CORPORATE PRESENTATION JANUARY 2020



A new generation of multi-functional cancer immunotherapies

Frank Bedu-Addo Ph.D. President & CEO



Forward-Looking Statements

This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words "anticipates," "may," "can," "plans," "believes," "estimates," "expects," "projects," "intends," "likely," "will," "should," "to be," and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those anticipated.

Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption "Risk Factors" in the documents filed with the Securities and Exchange Commission from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included in this presentation to reflect subsequent events or circumstances.

PDS Biotechnology leadership team has demonstrated success in the development and commercialization of leading pharmaceutical products

1	Frank Bedu-Addo, PhD Chief Executive Officer	 Senior executive experience with management of strategy and execution at both large pharma and biotechs Notable drug development: Abelcet[®] (Liposome Company/ Elan) PEG-Intron[®] (Schering-Plough/ Merck) 	CardinalHealth Schering-Plough
•	Andrew Saik Chief Financial Officer	 Senior executive experience with over 20 years of experience in pharma and drug development In-depth experience with M&A transactions, capital markets, and investor relations 	AUXILIUM Therapeutics, Inc. Cendo
•	Lauren V. Wood, MD Chief Medical Officer	 >30 years of translational clinical research experience Former Director of Clinical Research at the National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) 	NATIONAL CANCER INSTITUTE National Institute of Allergy and Infectious Diseases
	Gregory Conn, PhD Chief Scientific Officer	 Co-founder >35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing 	EVALUATE: EVALUATE: EVALUATE: EVALUATE: EVALUATE: EVALUAT: EVALU

PDS Biotech is well-poised to transform cancer treatment by fulfilling the promise of immuno-oncology

Powerful T-cell activating immunotherapy platform

Demonstrated potential for strong clinical efficacy and durability of the response with minimal toxicity

Diversified pipeline

3

Clinical studies in areas of high unmet medical need supported by leaders in the field



PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on the proprietary Versamune[®] platform

CORPORATE OVERVIEW	VERSAMUNE [®] PLATFORM	PIPELINE
 Publicly listed via reverse merger with Edge Therapeutics in March 2019 ~15 employees with headquarters in Princeton, NJ 5.2M shares outstanding with \$17.4M in cash* 	 Versatile and potent T-cell-activating platform Clinically validated induction of active antigen-specific killer and helper T-cells in vivo Promising clinical efficacy results in early trials of PDS0101 monotherapy with good safety and no dose limiting toxicities 	 PDS0101 (Phase 2): HPV- associated cancers (Anal, head & neck, cervical etc.) PDS0102 (Formulation complete): Prostate, breast cancers PDS0103: Ovarian, breast, colorectal and lung cancers PDS0104: Melanoma

PDS Biotech's pipeline combines the Versamune[®] platform with proprietary & validated tumor antigens across several cancer types

PRODUCT	INDICATION	COMBINATION	PC	P1	P2	P3	R	PARTNER(S)
PDS0101 (HPV16)	First line treatment of recurrent/ metastatic head and neck cancer	KEYTRUDA®						
PDS0101 (HPV16)	Advanced HPV-related cancers	ТВА						NIH NATIONAL CANCER INSTITUTE
<u>PDS0101</u> (HPV16)	Stage Ilb-IVa cervical cancer	Chemo-radiation						To be announced
<u>PDS0102</u> (<u>TARP)</u>	Prostate and breast cancer	Immunotherapy						NIH NATIONAL CANCER INSTITUTE
PDS0103 (MUC-1)	Breast, colorectal, ovarian and NSCLC cancer	Immunotherapy						NIH NATIONAL CANCER INSTITUTE
<u>PDS0104</u> (TRP2)	Melanoma	Immunotherapy						
	PDS Biotec	h Funded	Partner	Funded				

Versamune[®] Platform

E9



Versamune[®] is a proprietary T-cell activating platform engineered to induce a robust, targeted anti-tumor response *in vivo*



- Versamune[®] is based on proprietary, positively charged and immune activating lipids that form spherical nanoparticles in aqueous media
- The nanoparticles are sized to mimic viruses, which promotes excellent uptake by dendritic cells of the immune system
- Activates the important Type I interferon immunological signaling pathway
- Versamune[®] promotes the activation and maturation of dendritic cells, which then migrate to the lymph nodes

Versamune[®] has demonstrated the potential to overcome the challenges of immunotherapy



PDS Biotechnology

Reference: Gandhapudi SK, Ward M, Bush JPC, Bedu-Addo F, Conn G, Woodward JG. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536.

9

Greater quantity and quality of Versamune[®]-induced killer T-cells may result in unique ability to eradicate HPV-positive tumors after a single dose

Produces > 10-fold number of highly potent (polyfunctional) killer T-cells vs. other T-cell technologies



*Adjuvant = cytokine GMCSF

DS Biotechnology

References: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model with other immunotherapies reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, August 3, 27 (33): 5706

PDS0101



Approximately 43,000 patients are diagnosed with HPV-associated cancers each year, a number unlikely to be impacted by increased use of HPV preventive vaccines in the next decade



PDS0101 combines the utility of the Versamune[®] platform with a proprietary mix of HPV16 antigens, the most virulent high-risk HPV type and by far the most prevalent in patients with HPV-associated cancer



The combination of Versamune[®] and a proprietary antigen is engineered for simplicity and ease of administration







Vials of HPV16 mix (L) and Versamune[®] (R) Versamune[®] formulation is mixed before injection* Delivered via subcutaneous injection

PDS0101 Phase 1 clinical trial: Unique *in vivo* demonstration of high levels of HPV-specific killer T-cells in circulating blood

Clinical study results successfully demonstrate translation of Versamune®'s multifunctional mechanism of action between pre-clinical models and humans



Order of magnitude increase over baseline

INF-γ Elispot

Granzyme-b Elispot

<u>Clinical Study Results in</u> <u>Patients with CIN</u>

- Immunogenicity at Day 14
- Defined dose for Phase 2 studies (3mg)
- No dose-limiting toxicities

Follow-up of patients in PDS0101 Phase 1 study demonstrated promising clinical responses at all three tested doses



Biotechnology

- A post-hoc, retrospective analysis, demonstrated <u>complete lesion regression in at</u> least 60% of evaluable patients (6/10) as early as 1-3 months after treatment
 - No lesion recurrence occurred within the 2-year evaluation period
- Spontaneous regression of CIN1 occurs in about 44% of patients over a 2-year duration*
- These results were remarkably positive as most patients were infected with multiple high-risk HPV types
- Two patients who had regression by cytology were not considered clinical responders:
 - The first regressed to atypical cells of undetermined significance at the first posttreatment evaluation (3 months) but HPV detected
 - The second had complete regression by cytology at the first post-treatment evaluation (3 months) but had residual CIN by colposcopy

PDS Biotech clinical strategy in advanced cancer is to focus on efficiency and risk mitigation to proof of concept

Versamune[®]-based immunotherapies are being developed as combination therapies to exploit the demonstrated synergies between Versamune[®] and other anti-cancer agents

- Checkpoint inhibitors have shown confirmed clinical efficacy and have demonstrated clinical benefit in late stage cancer
 - Checkpoint inhibitors block a key immunological defense mechanism for cancer cells, and are reported to work primarily in patients whose immune systems are already generating tumorattacking CD8+ killer T-cells pre-treatment
- Using various tumor-specific proteins (antigens), Versamune[®] has demonstrated the unique ability to generate large and superior numbers of CD8+ killer T-cells that effectively recognize and kill antigenexpressing cancer cells in pre-clinical and human clinical studies

PDS Biotech is developing a new generation of advanced cancer treatments combining Versamune[®]-based immunotherapies with checkpoint inhibitors and other standard of care therapies



The robust T-cell response induced by Versamune[®] results in the potential for enhancement of efficacy of checkpoint inhibitors in immune suppressive B16 melanoma

Early clinical studies showed the checkpoint inhibitor to be ineffective in treating B16 melanoma, a notoriously difficult model to treat.

Versamune[®] + TRP2 melanoma antigen (sub-optimal levels) promotes infiltration of active killer T-cells into tumors, strong synergy with the checkpoint inhibitor, and significantly enhanced anti-tumor efficacy



PDS Biotechnology

Reference: Gandhapudi SK, Ward M, Bush JPC, Bedu-Addo F, Conn G, Woodward JG. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536.

PDS0101 is the only compound selected by Merck for evaluation in combination with KEYTRUDA[®] as first line cancer therapy

- PDS0101 + KEYTRUDA[®]
 - Keytruda[®] first immunotherapy approved as standard of care for first line treatment of cancer (recurrent or metastatic head and neck cancer)
 - PDS0101 first T-cell activating immunotherapy to demonstrate both high levels of circulating CD8+ killer Tcells and therapeutic benefit as monotherapy
 - Unique immuno-oncology combination addressing first-line treatment of cancer
 - Validation of both efficacy and safety of PDS0101
 - Anticipated advantages of combining PDS0101 with standard of care:
 - Mitigated risk
 - Potential enhanced rates of recruitment
 - Potential for rapid market penetration and market leadership

Initiate Phase 2 in 1H 2020



A Phase 2 study of PDS0101 in combination with KEYTRUDA[®] in first-line treatment of recurrent/metastatic head and neck cancer is planned for 1H 2020

- PDS Biotechnology-sponsored study with KEYTRUDA[®] supplied by Merck
- Primary endpoints: Efficacy, safety and tolerability
- Study design: Phase 2 open-label study
- Inclusion criteria: Recurrent/metastatic head and neck cancer and HPV16 infection



- Expected data reads:
 - Safety analysis of first 12 patients after Cycle 1: 4Q 2020
 - Interim analysis planned: 2H 2021

Investigator-Led Phase 2 studies of PDS0101 in combination therapy will evaluate efficacy and safety in treatment of advanced HPV cancers

Funded By	Phase 2 Open Label Study (Safety and Efficacy)	Important Considerations	Expected Initiation
NATIONAL CANCER INSTITUTE	 Advanced HPV-related cancers – all types Triple combination with <u>large-pharma</u> <u>owned</u> novel checkpoint inhibitor (CPI) and immuno-cytokine 30 subjects 	 NCI selection and confirmation of synergies with PDS0101 All three agents have demonstrated efficacy as monotherapies in early trials 	1H 2020
Leading Cancer Research Institute: TBA	 Advanced, localized cervical cancer (Stage IIb-IVa) Combination with chemo-radiotherapy (CRT-standard of care) 35 subjects 	 T-cell induction has strong potential to enhance CRT anti-cancer efficacy Mitigated risk Potential for rapid market penetration and market leadership 	1H 2020

PDS0102

LaC's

39

105



PDS0102 combines a proven NCI-developed TARP antigen with Versamune[®] to promote the robust induction of prostate- and breast-specific killer T-cells

- PDS Biotech collaboration with the National Cancer Institute (NCI)
- The TARP antigen was discovered by the NCI to be present in over 85% of prostate cancers and 50% of breast cancers
- The NCI demonstrated that the TARP antigen is recognized by T-cells of late-stage cancer patients, with vaccination resulting in a significant lowering of tumor growth rate*
 - PDS Biotech is combining the TARP antigen with Versamune[®] (PDS0102) to potentially promote more effective induction of prostate and breast-specific killer T-cells and altering of the tumor microenvironment
 - In on-going pre-clinical studies Versamune[®], has demonstrated the ability to significantly enhance the immune system's ability to generate TARP-specific killer T-cells

Intellectual Property and Financials



Intellectual property provides multiple layers of technology and product protection for Versamune[®]-related products through mid-2030s

- Versamune[®] and associated patents are owned and licensed by PDS Biotech
- Patents cover <u>methods and compositions</u> stimulating/promoting an immune response with Versamune[®] technology in various forms and mechanisms <u>through 2034</u>
 - Use of specific cationic lipids to induce an immune response
 - Compositions and use of any cationic lipid to activate MAP kinase
 - Compositions and use of R-DOTAP to induce immune response
 - Micellar antigen + cationic lipids compositions (US still ongoing)
 - Compositions of R-DOTAP with GM-CSF to reduce immune suppressive myeloid derived suppressor cells in the tumor
- Five issued international patent families (including Europe and Japan)

PDS Biotech is in a financial position to support critical near-term milestones

Nasdaq:	PDSB
Shares Outstanding ¹	5.2M
Cash ¹	\$17.4M
Share Price ²	\$2.53
Market Cap ²	\$14.6M
Debt ¹	

- 1H 2020: Initiation of PDS Biotech-Merck Phase 2 combination study in head and neck cancer
- 1H 2020: Initiation of PDS Biotech-NCI Phase 2 combination study in advanced HPV-cancers
- 1H 2020: Initiation of Partnered Phase 2 combination study in advanced cervicalcancer
- 3Q 2020: Complete formulation of PDS0102

PDS Biotech is well-poised to transform cancer treatment by fulfilling the promise of immuno-oncology

Powerful T-cell activating immunotherapy platform

Demonstrated potential for strong clinical efficacy and durability of the response with minimal toxicity

Diversified pipeline

3

Clinical studies in areas of high unmet medical need supported by leaders in the field





A new generation of multi-functional cancer immunotherapies

1003